Prevalence of pathogenic variants in cancer-predisposing genes in second cancer after childhood solid cancers

Cancer Med. 2023 May;12(10):11264-11273. doi: 10.1002/cam4.5835. Epub 2023 Apr 6.

Abstract

Background: Second malignant neoplasms (SMNs) are one of the most severe late complications after pediatric cancer treatment. However, the effect of genetic variation on SMNs remains unclear. In this study, we revealed germline genetic factors that contribute to the development of SMNs after treatment of pediatric solid tumors.

Methods: We performed whole-exome sequencing in 14 pediatric patients with SMNs, including three brain tumors.

Results: Our analysis revealed that five of 14 (35.7%) patients had pathogenic germline variants in cancer-predisposing genes (CPGs), which was significantly higher than in the control cohort (p < 0.01). The identified genes with variants were TP53 (n = 2), DICER1 (n = 1), PMS2 (n = 1), and PTCH1 (n = 1). In terms of the type of subsequent cancer, leukemia and multiple episodes of SMN had an exceptionally high rate of CPG pathogenic variants. None of the patients with germline variants had a family history of SMN development. Mutational signature analysis showed that platinum drugs contributed to the development of SMN in three cases, which suggests the role of platinum agents in SMN development.

Conclusions: We highlight that overlapping effects of genetic background and primary cancer treatment contribute to the development of second cancers after treatment of pediatric solid tumors. A comprehensive analysis of germline and tumor samples may be useful to predict the risk of secondary cancers.

Keywords: cancer predisposition; childhood solid cancer; second malignant neoplasms.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brain Neoplasms* / complications
  • Child
  • DEAD-box RNA Helicases / genetics
  • Genetic Predisposition to Disease
  • Germ-Line Mutation
  • Humans
  • Leukemia*
  • Neoplasms, Second Primary* / epidemiology
  • Neoplasms, Second Primary* / genetics
  • Platinum
  • Prevalence
  • Ribonuclease III / genetics

Substances

  • Platinum
  • DICER1 protein, human
  • Ribonuclease III
  • DEAD-box RNA Helicases